Nasdaq · CIK 0001398733
AQST Aquestive Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 26 d ago. Close $4.78 on Oct 9, 2026, +62% from the 52-week low and -36% from the high.
Last 90 days
Net insider value
-$166k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
2
$166k by 2 insiders
Insiders on file
16
with a Form 4 at this company
Price and insider trades, last year
AQSTOct 9, 2026 · close 4.78
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Aquestive Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Daniel Barber President and CEO sell | $120k 25,000 shares | -4% | - | |
| 0Weak | Sherry Korczynski Chief Commercial Officer sell | $46k 8,750 shares | -4% | - | |
| 40Moderate | Cassie Jung Chief Operating Officer sell | $214 44 shares | -100% | - |
Transactions
The last 52 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Daniel Barber President and CEO | SOpen-market sale Common Stock10b5-1 | -25,000 | $4.82 | $120k | 652,317 | 26 d ago |
| Sep 9, 2026 | Sherry Korczynski Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +8,750 | $2.65 | $23k | 244,439 | 31 d ago |
| Sep 9, 2026 | Sherry Korczynski Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -8,750 | $5.22 | $46k | 235,689 | 31 d ago |
| Sep 9, 2026 | Sherry Korczynski Chief Commercial Officer | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -8,750 | $0.00 | $0 | 26,250 | 31 d ago |
| Sep 9, 2026 | Peter E. Boyd Chief People Officer | XIn-the-money exercise Common Stock | +2,293 | $0.96 | $2,201 | 284,024 | 32 d ago |
| Sep 9, 2026 | Peter E. Boyd Chief People Officer | XIn-the-money exercise Warrant (Right to Buy)derivative | -2,293 | $0.00 | $0 | 0 | 32 d ago |
| Sep 8, 2026 | Daniel Barber President and CEO | XIn-the-money exercise Common Stock | +91,743 | $0.96 | $88k | 677,317 | 33 d ago |
| Sep 8, 2026 | Daniel Barber President and CEO | XIn-the-money exercise Warrant (Right to Buy)derivative | -91,743 | $0.00 | $0 | 0 | 33 d ago |
| Sep 3, 2026 | Cassie Jung Chief Operating Officer | XIn-the-money exercise Common Stock | +4,587 | $0.96 | $4,404 | 206,833 | 34 d ago |
| Sep 3, 2026 | Cassie Jung Chief Operating Officer | XIn-the-money exercise Warrant (Right to Buy)derivative | -4,587 | $0.00 | $0 | 0 | 34 d ago |
| Jun 11, 2025 | Marco Taglietti director | AGrant or award Stock Option (Right to Purchase)derivative | +42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 11, 2025 | Abigail L. Jenkins director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | -42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 11, 2025 | Timothy E Morris director | AGrant or award Stock Option (right to purchase)derivative | +42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 11, 2025 | Julie Krop director | AGrant or award Stock Option (Right to Purchase)derivative | +42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 11, 2025 | Gregory B Brown director | AGrant or award Stock Option (Right to Purchase)derivative | +42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 11, 2025 | John Cochran director | AGrant or award Stock Option (Right to Purchase)derivative | +42,000 | $3.41 | $143k | 42,000 | Jun 12, 2025 |
| Jun 9, 2025 | Sherry Korczynski SVP Sales and Marketing | FTax withholding Common Stock | -2,714 | $3.54 | $9,608 | 156,858 | Jun 10, 2025 |
| May 15, 2025 | Melina Cioffi SVP, Regulatory Affairs | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 202,261 | May 15, 2025 |
| Mar 7, 2025 | Stephen Wargacki Chief Science Officer | AGrant or award Common Stock | +115,000 | $0.00 | $0 | 376,414 | Mar 11, 2025 |
| Mar 7, 2025 | A Ernest Toth Jr Chief Financial Officer | AGrant or award Common Stock | +110,000 | $0.00 | $0 | 358,295 | Mar 11, 2025 |
| Mar 7, 2025 | Carl N Kraus Chief Medical Officer | AGrant or award Common Stock | +70,000 | $0.00 | $0 | 321,681 | Mar 11, 2025 |
| Mar 7, 2025 | Sherry Korczynski SVP Sales and Marketing | AGrant or award Common Stock | +90,000 | $0.00 | $0 | 165,000 | Mar 11, 2025 |
| Mar 7, 2025 | Lori J Braender Chief Legal Officer | AGrant or award Common Stock | +110,000 | $0.00 | $0 | 423,231 | Mar 11, 2025 |
| Mar 7, 2025 | Peter E. Boyd See Remark | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 317,628 | Mar 11, 2025 |
| Mar 7, 2025 | Daniel Barber President and CEO | AGrant or award Common Stock | +272,000 | $0.00 | $0 | 1,098,478 | Mar 11, 2025 |
| Mar 7, 2025 | Cassie Jung Chief Operating Officer | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 313,066 | Mar 11, 2025 |
| Mar 7, 2025 | A Ernest Toth Jr Chief Financial Officer | FTax withholding Common Stock | -10,193 | $2.65 | $27k | 348,102 | Mar 11, 2025 |
| Mar 7, 2025 | Carl N Kraus Chief Medical Officer | FTax withholding Common Stock | -8,115 | $2.65 | $22k | 313,566 | Mar 11, 2025 |
| Mar 7, 2025 | Sherry Korczynski SVP Sales and Marketing | FTax withholding Common Stock | -5,428 | $2.65 | $14k | 159,572 | Mar 11, 2025 |
| Mar 7, 2025 | Lori J Braender Chief Legal Officer | FTax withholding Common Stock | -9,592 | $2.65 | $25k | 413,639 | Mar 11, 2025 |
| Mar 7, 2025 | Peter E. Boyd See Remark | FTax withholding Common Stock | -6,624 | $2.65 | $18k | 311,004 | Mar 11, 2025 |
| Mar 7, 2025 | Stephen Wargacki Chief Science Officer | FTax withholding Common Stock | -12,859 | $2.65 | $34k | 363,555 | Mar 11, 2025 |
| Mar 7, 2025 | Daniel Barber President and CEO | FTax withholding Common Stock | -29,307 | $2.65 | $78k | 1,069,171 | Mar 11, 2025 |
| Mar 7, 2025 | Cassie Jung Chief Operating Officer | FTax withholding Common Stock | -7,361 | $2.65 | $20k | 305,705 | Mar 11, 2025 |
| Mar 9, 2025 | Lori J Braender Chief Legal Officer | FTax withholding Common Stock | -10,658 | $2.65 | $28k | 402,981 | Mar 11, 2025 |
| Mar 9, 2025 | A Ernest Toth Jr Chief Financial Officer | FTax withholding Common Stock | -8,736 | $2.65 | $23k | 339,366 | Mar 11, 2025 |
| Mar 9, 2025 | Peter E. Boyd See Remark | FTax withholding Common Stock | -7,681 | $2.65 | $20k | 303,323 | Mar 11, 2025 |
| Mar 7, 2025 | Sherry Korczynski SVP Sales and Marketing | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Mar 11, 2025 |
| Mar 9, 2025 | Daniel Barber President and CEO | FTax withholding Common Stock | -53,998 | $2.65 | $143k | 1,015,173 | Mar 11, 2025 |
| Mar 7, 2025 | Carl N Kraus Chief Medical Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Mar 11, 2025 |
| Mar 9, 2025 | Stephen Wargacki Chief Science Officer | FTax withholding Common Stock | -15,431 | $2.65 | $41k | 348,124 | Mar 11, 2025 |
| Mar 9, 2025 | Cassie Jung Chief Operating Officer | FTax withholding Common Stock | -7,997 | $2.65 | $21k | 297,708 | Mar 11, 2025 |
| Mar 7, 2025 | A Ernest Toth Jr Chief Financial Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 11, 2025 |
| Mar 10, 2025 | Stephen Wargacki Chief Science Officer | FTax withholding Common Stock | -4,572 | $2.54 | $12k | 343,552 | Mar 11, 2025 |
| Mar 7, 2025 | Lori J Braender Chief Legal Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Mar 11, 2025 |
| Mar 7, 2025 | Peter E. Boyd See Remark | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Mar 11, 2025 |
| Mar 7, 2025 | Daniel Barber President and CEO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +408,000 | $0.00 | $0 | 408,000 | Mar 11, 2025 |
| Mar 10, 2025 | Cassie Jung Chief Operating Officer | FTax withholding Common Stock | -2,182 | $2.54 | $5,542 | 295,526 | Mar 11, 2025 |
| Mar 7, 2025 | Stephen Wargacki Chief Science Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Mar 11, 2025 |
| Mar 7, 2025 | Cassie Jung Chief Operating Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Mar 11, 2025 |
| Dec 2, 2024 | Douglas K Bratton owner | GGift Common Stockindirect: See Footnote | -40,000 | $0.00 | $0 | 199,841 | Dec 4, 2024 |
| Nov 26, 2024 | Cassie Jung Chief Operating Officer | SOpen-market sale Common Stockindirect: by spouse IRA | -44 | $4.87 | $214 | 0 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Lori J BraenderChief Legal Officer
- Douglas K Brattonowner
- Gregory B Browndirector
- Daniel BarberPresident and CEO
- Peter E. BoydChief People Officer
- Melina CioffiSVP, Regulatory Affairs
- John Cochrandirector
- Abigail L. Jenkinsdirector
- Cassie JungChief Operating Officer
- Sherry KorczynskiSVP Sales and Marketing
- Carl N KrausChief Medical Officer
- Julie Kropdirector
- Timothy E Morrisdirector
- A Ernest Toth JrChief Financial Officer
- Marco Tagliettidirector
- Stephen WargackiChief Science Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.